Trial Profile
209233: Compassionate Use Individual Request Program for Belantamab Mafodotin in Multiple Myeloma 213304: Expanded Access Program for Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma Who Are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 22 Dec 2022
Price :
$35
*
At a glance
- Drugs Belantamab mafodotin (Primary)
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 09 Mar 2021 Status changed from recruiting to completed.
- 12 Dec 2018 New trial record